‘My son can now enjoy life’: Children with severe form of epilepsy helped by new drug

• Fenfluramine has demonstrated clinical benefit in children with Dravet syndrome, a severe and treatment-resistant form of early-onset epilepsy, with families reporting significant improvements in quality of life and seizure control.
• This represents a breakthrough for a previously difficult-to-manage condition where many standard antiepileptic drugs prove ineffective, offering new therapeutic options for this paediatric population.
• The drug's availability may alter management pathways for Dravet syndrome, warranting review of diagnostic protocols and referral criteria to identify eligible children who could benefit from this treatment.

Families say the groundbreaking medicine is transforming the lives of children with Dravet syndrome.

ClinicaliQ summarises and contextualises external updates for clinical awareness, then links to the original publisher for the full article and most current context.